Part 5: Unproven cell therapies and the commercialization of cell-based products.

@article{Deans2016Part5U,
  title={Part 5: Unproven cell therapies and the commercialization of cell-based products.},
  author={Robert J. Deans and Kurt C. Gunter and Massimo Dominici and Miguel Forte},
  journal={Cytotherapy},
  year={2016},
  volume={18 1},
  pages={
          138-42
        }
}
Rubius Therapeutics, Cambridge, Massachusetts, USA. Past Chair, International Society for Cellular Therapy (ISCT) Commercialization Committee 2010–2014, Cell Medica Inc., Houston,Texas, USA. Immediate Past ISCT President, 2012–2014, and Chair, ISCT Advisory Board, 2014–2016, Division of Oncology, Laboratory of Cellular Therapy, University of Modena and Reggio Emilia, Modena, Italy. ISCT President 2014–2016, and Chair of the ISCT Presidential Task Force on the Use of Unproven Cellular Therapies… CONTINUE READING
BETA

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-6 OF 6 REFERENCES

The political economy of the global stem cell therapy market.London:King’s College London;2013

  • B Salter, Y Zhou, S. Datta
  • 2013
2 Excerpts

Medical tourism: treatments, markets and health system implications: a scoping review. Organisation for Economic Co-operation and Development

  • N Lunt, R Smith, M Exworthy, ST Green, D Horsfall, R. Mannion
  • <http://www.oecd.org/els/health-systems/ 48723982…
  • 2011
1 Excerpt

Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy

  • ED Thomas, Lochte HL, WC Lu, JW Ferrebee
  • N Engl J Med
  • 1957
1 Excerpt

Similar Papers

Loading similar papers…